Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.57
ARIA's Cash-to-Debt is ranked lower than
86% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. ARIA: 0.57 )
Ranked among companies with meaningful Cash-to-Debt only.
ARIA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36  Med: 5.53 Max: 24.17
Current: 0.57
0.36
24.17
Equity-to-Asset -0.07
ARIA's Equity-to-Asset is ranked lower than
93% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARIA: -0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
ARIA' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.2  Med: 0.58 Max: 0.89
Current: -0.07
-2.2
0.89
Piotroski F-Score: 4
Altman Z-Score: 1.61
Beneish M-Score: -2.02
WACC vs ROIC
26.94%
-99.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -73.62
ARIA's Operating Margin % is ranked higher than
51% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. ARIA: -73.62 )
Ranked among companies with meaningful Operating Margin % only.
ARIA' s Operating Margin % Range Over the Past 10 Years
Min: -36749.1  Med: -734.05 Max: 58.61
Current: -73.62
-36749.1
58.61
Net Margin % -16.99
ARIA's Net Margin % is ranked higher than
63% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. ARIA: -16.99 )
Ranked among companies with meaningful Net Margin % only.
ARIA' s Net Margin % Range Over the Past 10 Years
Min: -39582.8  Med: -782.73 Max: 47.63
Current: -16.99
-39582.8
47.63
ROA % -5.41
ARIA's ROA % is ranked higher than
72% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. ARIA: -5.41 )
Ranked among companies with meaningful ROA % only.
ARIA' s ROA % Range Over the Past 10 Years
Min: -120.13  Med: -80.44 Max: 92.14
Current: -5.41
-120.13
92.14
ROC (Joel Greenblatt) % -2.19
ARIA's ROC (Joel Greenblatt) % is ranked higher than
76% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. ARIA: -2.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARIA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3088.06  Med: -884.82 Max: 1083.41
Current: -2.19
-3088.06
1083.41
3-Year Revenue Growth Rate 494.40
ARIA's 3-Year Revenue Growth Rate is ranked higher than
100% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ARIA: 494.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARIA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 23.7 Max: 494.4
Current: 494.4
0
494.4
3-Year EBITDA Growth Rate -5.70
ARIA's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. ARIA: -5.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARIA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -16.2  Med: 2.7 Max: 36
Current: -5.7
-16.2
36
3-Year EPS without NRI Growth Rate -2.80
ARIA's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. ARIA: -2.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARIA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -18.4  Med: -1.3 Max: 24.7
Current: -2.8
-18.4
24.7
GuruFocus has detected 5 Warning Signs with ARIAD Pharmaceuticals Inc $ARIA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ARIA Guru Trades in Q1 2016

Paul Tudor Jones 27,069 sh (+37.62%)
Michael Price 1,075,000 sh (+31.10%)
Chuck Royce 375,352 sh (unchged)
Jim Simons 497,384 sh (-35.98%)
» More
Q2 2016

ARIA Guru Trades in Q2 2016

Steven Cohen 300,000 sh (New)
Michael Price 1,075,000 sh (unchged)
Chuck Royce 375,352 sh (unchged)
Paul Tudor Jones 21,400 sh (-20.94%)
Jim Simons 81,696 sh (-83.57%)
» More
Q3 2016

ARIA Guru Trades in Q3 2016

Joel Greenblatt 154,887 sh (New)
Louis Moore Bacon 50,000 sh (New)
Jim Simons 1,358,181 sh (+1562.48%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Michael Price 940,000 sh (-12.56%)
Chuck Royce 269,352 sh (-28.24%)
» More
Q4 2016

ARIA Guru Trades in Q4 2016

Joel Greenblatt 210,936 sh (+36.19%)
Michael Price 940,000 sh (unchged)
Jim Simons 762,481 sh (-43.86%)
Chuck Royce 55,502 sh (-79.39%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ACAD, NAS:ALNY, NAS:TECH, NAS:IONS, NAS:GLPG, NAS:ICPT, NAS:RARE, NAS:CBPO, NAS:CLVS, NAS:BLUE, NYSE:XON, NAS:KITE, OTCPK:BTGGF, NAS:EXEL, NAS:JUNO, NAS:SAGE, NAS:AGIO, NAS:LGND, NAS:UTHR, OTCPK:ABCZF » details
Traded in other countries:APS.Germany, ARIA.Switzerland, 0R2K.UK,
ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788.

ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.

Ratios

vs
industry
vs
history
PS Ratio 24.78
ARIA's PS Ratio is ranked lower than
63% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. ARIA: 24.78 )
Ranked among companies with meaningful PS Ratio only.
ARIA' s PS Ratio Range Over the Past 10 Years
Min: 1.7  Med: 26.97 Max: 5517.5
Current: 24.78
1.7
5517.5
EV-to-EBITDA 524.26
ARIA's EV-to-EBITDA is ranked lower than
98% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. ARIA: 524.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARIA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -87.2  Med: -5.8 Max: 524.26
Current: 524.26
-87.2
524.26
Current Ratio 3.17
ARIA's Current Ratio is ranked lower than
60% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ARIA: 3.17 )
Ranked among companies with meaningful Current Ratio only.
ARIA' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 4.02 Max: 15.1
Current: 3.17
0.62
15.1
Quick Ratio 3.15
ARIA's Quick Ratio is ranked lower than
58% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. ARIA: 3.15 )
Ranked among companies with meaningful Quick Ratio only.
ARIA' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 3.95 Max: 14.95
Current: 3.15
0.52
14.95
Days Inventory 149.87
ARIA's Days Inventory is ranked lower than
59% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. ARIA: 149.87 )
Ranked among companies with meaningful Days Inventory only.
ARIA' s Days Inventory Range Over the Past 10 Years
Min: 8.07  Med: 48.84 Max: 179.13
Current: 149.87
8.07
179.13
Days Sales Outstanding 46.99
ARIA's Days Sales Outstanding is ranked higher than
62% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. ARIA: 46.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARIA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.49  Med: 29.08 Max: 287.59
Current: 46.99
0.49
287.59
Days Payable 1.00
ARIA's Days Payable is ranked lower than
96% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. ARIA: 1.00 )
Ranked among companies with meaningful Days Payable only.
ARIA' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 755.92 Max: 2937.44
Current: 1
1
2937.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.30
ARIA's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ARIA: -4.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARIA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -31.3  Med: -13.6 Max: -4.1
Current: -4.3
-31.3
-4.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.92
ARIA's Price-to-Median-PS-Value is ranked higher than
57% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. ARIA: 0.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARIA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 1.79 Max: 183.33
Current: 0.92
0.04
183.33
Earnings Yield (Greenblatt) % -0.10
ARIA's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. ARIA: -0.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARIA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.1  Med: 25.65 Max: 41.7
Current: -0.1
-0.1
41.7

More Statistics

Revenue (TTM) (Mil) $186.2
EPS (TTM) $ -0.18
Beta3.52
Short Percentage of Float16.07%
52-Week Range $4.67 - 23.99
Shares Outstanding (Mil)194.20

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 197 205 282 394
EPS ($) -0.44 -0.19 -0.29 0.07
EPS without NRI ($) -0.44 -0.19 -0.29 0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Feb 16 2017
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc. Feb 16 2017
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib Feb 07 2017
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 06 2017
Ariad Submits Marketing Application to EU Agency Feb 06 2017
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European... Feb 06 2017
Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy... Feb 01 2017
Takeda Reports Q3 FY2016 Results and Improves Year-End Outlook Feb 01 2017
Ariad mum on layoffs in letter to employees: ‘It’s business as usual’ Jan 25 2017
Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC Jan 20 2017
Ariad played hardball to boost Takeda buyout price, federal filings show Jan 20 2017
Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017 Jan 20 2017
Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)? Jan 20 2017
Takeda Commences Cash Tender Offer for All Outstanding Shares of ARIAD Pharmaceuticals, Inc. Jan 19 2017
Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders Jan 18 2017
Jazz Begins Phase III Study for Label Expansion of Defitelio Jan 18 2017
Becton, Dickinson Commercially Launches Precise WTA Kits Jan 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)